# Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

> **NCT05294731** · PHASE1,PHASE2 · RECRUITING · sponsor: **BeiGene** · enrollment: 146 (estimated)

## Conditions studied

- B-cell Malignancy
- Non-Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Waldenström Macroglobulinemia
- Marginal Zone Lymphoma
- Follicular Lymphoma
- DLBCL Unclassifiable
- Richter's Transformation

## Interventions

- **DRUG:** BGB-16673

## Key facts

- **NCT ID:** NCT05294731
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-06
- **Primary completion:** 2029-01-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05294731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05294731, "Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05294731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*